---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-036937"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:15:04.175434+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics reports Q4 net loss of $3.0M, cash $4.0M; CAD-1005 FDA EOP2 meeting completed

## Summary
- Q4 2025 net loss $3.0M vs $4.2M YoY; R&D expenses $0.7M vs $1.5M; G&A $2.4M vs $2.7M.
- Cash and equivalents $4.0M at Dec 31, 2025; evaluating financing and strategic alternatives to support clinical development.
- Completed End-of-Phase 2 FDA meeting on March 26, 2026 for CAD-1005; Phase 3 pivotal trial protocol incorporation underway.
- Phase 2 HIT study showed >25% absolute reduction in thrombotic events with CAD-1005 vs placebo on standard anticoagulation.
- CAD-1005 has Orphan Drug and Fast Track designations from FDA; orphan status from EMA.

## SEC filing metadata
- accession: 0001213900-26-036937
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390026036937/0001213900-26-036937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390026036937/ea0284258-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-036937
- JSON: https://secwatch.observer/filing/0001213900-26-036937.json
- Plain text: https://secwatch.observer/filing/0001213900-26-036937.txt

## Key facts
- Earnings Releases
  Cadrenal Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income $3.0 million for the quarter ending December 31, 2025.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Net income: $3.0 million for the quarter ending December 31, 2025
  - Result: reported results
  source text: Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390026036937/0001213900-26-036937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.